Robert Dreicer

26.2k total citations · 6 hit papers
188 papers, 12.8k citations indexed

About

Robert Dreicer is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Robert Dreicer has authored 188 papers receiving a total of 12.8k indexed citations (citations by other indexed papers that have themselves been cited), including 161 papers in Pulmonary and Respiratory Medicine, 85 papers in Oncology and 58 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Robert Dreicer's work include Prostate Cancer Treatment and Research (154 papers), Radiopharmaceutical Chemistry and Applications (57 papers) and Prostate Cancer Diagnosis and Treatment (44 papers). Robert Dreicer is often cited by papers focused on Prostate Cancer Treatment and Research (154 papers), Radiopharmaceutical Chemistry and Applications (57 papers) and Prostate Cancer Diagnosis and Treatment (44 papers). Robert Dreicer collaborates with scholars based in United States, France and United Kingdom. Robert Dreicer's co-authors include Celestia S. Higano, Philip W. Kantoff, Eric J. Small, Charles H. Redfern, Neal D. Shore, Robert B. Sims, Yi Xu, Anna C. Ferrari, Paul F. Schellhammer and Mark W. Frohlich and has published in prestigious journals such as Nature, New England Journal of Medicine and Journal of Clinical Oncology.

In The Last Decade

Robert Dreicer

181 papers receiving 12.6k citations

Hit Papers

Sipuleucel-T Immunotherapy for Castration-Resistant Prost... 2008 2026 2014 2020 2010 2015 2008 2018 2023 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
    2010 4.1k citations Philip W. Kantoff, Celestia S. Higano et al. profile →
  2. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
    2015 1.8k citations Noah M. Hahn, Robert Dreicer et al. profile →
  3. Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
    2008 1.7k citations Howard I. Scher, Cora N. Sternberg et al. Journal of Clinical Oncology profile →
  4. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
    2018 695 citations Noah M. Hahn, Daniel H. Shevrin et al. Journal of Clinical Oncology profile →
  5. Updates to Advanced Prostate Cancer: AUA/SUO Guideline (2023)
    2023 132 citations Robert Dreicer et al. profile →
  6. Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC).
    2022 125 citations Xīn Gào, Howard A. Burris et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert Dreicer United States 36 8.6k 4.9k 3.1k 2.8k 2.7k 188 12.8k
William Kevin Kelly United States 46 6.3k 0.7× 3.9k 0.8× 1.9k 0.6× 765 0.3× 2.0k 0.8× 244 11.9k
Shahneen Sandhu Australia 46 5.9k 0.7× 6.0k 1.2× 2.5k 0.8× 1.3k 0.5× 2.1k 0.8× 289 11.0k
Glenn Liu United States 46 4.9k 0.6× 2.8k 0.6× 2.0k 0.7× 905 0.3× 1.8k 0.7× 175 8.5k
David Olmos United Kingdom 48 6.3k 0.7× 4.1k 0.8× 1.4k 0.5× 516 0.2× 3.2k 1.2× 233 10.4k
Amita Patnaik United States 62 4.5k 0.5× 8.4k 1.7× 981 0.3× 2.7k 1.0× 2.1k 0.8× 365 14.4k
Sara M. Tolaney United States 54 5.3k 0.6× 11.6k 2.4× 2.0k 0.7× 1.7k 0.6× 3.7k 1.4× 502 14.8k
Anthony M. Joshua Canada 44 3.4k 0.4× 3.9k 0.8× 1.4k 0.4× 1.4k 0.5× 1.6k 0.6× 326 7.8k
Ian E. Krop United States 68 5.4k 0.6× 13.9k 2.8× 5.7k 1.9× 1.7k 0.6× 4.0k 1.5× 298 19.0k
Ronit Simantov United States 36 4.3k 0.5× 3.3k 0.7× 647 0.2× 1.4k 0.5× 2.6k 1.0× 88 11.2k
A Płużańska Poland 28 8.3k 1.0× 6.3k 1.3× 1.4k 0.5× 419 0.2× 2.9k 1.1× 65 11.6k

Countries citing papers authored by Robert Dreicer

Since Specialization
Citations

This map shows the geographic impact of Robert Dreicer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Dreicer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Dreicer more than expected).

Fields of papers citing papers by Robert Dreicer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Dreicer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Dreicer. The network helps show where Robert Dreicer may publish in the future.

Co-authorship network of co-authors of Robert Dreicer

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Dreicer. A scholar is included among the top collaborators of Robert Dreicer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Dreicer. Robert Dreicer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Vaishampayan, Ulka N., Robert Dreicer, Elisabeth I. Heath, et al.. (2024). A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancer. European Journal of Cancer. 202. 114007–114007. 3 indexed citations
2.
Gào, Xīn, Howard A. Burris, Jacqueline Vuky, et al.. (2022). Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 40(6_suppl). 17–17. 125 indexed citations breakdown →
3.
Aragon‐Ching, Jeanny B. & Robert Dreicer. (2020). Treatment in hormone-sensitive metastatic prostate cancer: factors to consider when personalizing therapy. Expert Review of Anticancer Therapy. 20(6). 483–490. 3 indexed citations
4.
Antonarakis, Emmanuel S., Pedro Isaacsson Velho, Wei Fu, et al.. (2020). CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors. JCO Precision Oncology. 4(4). 370–381. 144 indexed citations
5.
Halwani, Ahmad, Vikas Patil, Zachary Burningham, et al.. (2019). Real-world practice patterns in veterans with metastatic castration-resistant prostate cancer. Urologic Oncology Seminars and Original Investigations. 38(1). 1.e1–1.e10. 19 indexed citations
6.
Wit, Ronald de, Ashish M. Kamat, Joaquim Bellmunt, et al.. (2016). Pembrolizumab in patients with Bacillus Calmette Guérin (BCG)-unresponsive, high-risk non–muscle-invasive bladder cancer (NMIBC): Phase 2 KEYNOTE-057 study. Annals of Oncology. 27. vi294–vi294. 2 indexed citations
7.
Autio, Karen A., Jorge A. García, Ajjai Alva, et al.. (2016). A phase 2 study of BIND-014 (PSMA-targeted docetaxel nanoparticle) administered to patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 34(2_suppl). 233–233. 28 indexed citations
8.
Zhao, Bo, Nitin Yerram, Tianming Gao, Robert Dreicer, & Eric A. Klein. (2015). Long-term survival of patients with locally advanced prostate cancer managed with neoadjuvant docetaxel and radical prostatectomy. Urologic Oncology Seminars and Original Investigations. 33(4). 164.e19–164.e23. 16 indexed citations
9.
McNeel, Douglas G., Thomas A. Gardner, Celestia S. Higano, et al.. (2014). A Transient Increase in Eosinophils Is Associated with Prolonged Survival in Men with Metastatic Castration-Resistant Prostate Cancer Who Receive Sipuleucel-T. Cancer Immunology Research. 2(10). 988–999. 44 indexed citations
10.
Dreicer, Robert, David B. MacLean, Ajit Suri, et al.. (2014). Phase I/II Trial of Orteronel (TAK-700)—an Investigational 17,20-Lyase Inhibitor—in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 20(5). 1335–1344. 34 indexed citations
11.
12.
Dreicer, Robert. (2013). Safety, pharmacokinetics, and efficacy of TAK-700 in castration-resistant, metastatic prostate cancer: A phase I/II, open-label study. Clinical and Experimental Pharmacology. 3 indexed citations
13.
Dreicer, Robert, et al.. (2013). Intermittent Androgen Deprivation Therapy for Metastatic Prostate Cancer. Journal watch. 2013. 7 indexed citations
14.
Dreicer, Robert, et al.. (2011). Neoadjuvant Androgen-Deprivation Therapy for Prostate Cancer. Journal watch. 2011. 1 indexed citations
15.
Dreicer, Robert, Dean F. Bajorin, David G. McLeod, Daniel P. Petrylak, & Judd W. Moul. (2011). New Data, New Paradigms for Treating Prostate Cancer Patients—VI: Novel Hormonal Therapy Approaches. Urology. 78(5). S494–S498. 12 indexed citations
16.
Moul, Judd W., Christopher P. Evans, Leonard G. Gomella, Mack Roach, & Robert Dreicer. (2011). Traditional Approaches to Androgen Deprivation Therapy. Urology. 78(5). S485–S493. 5 indexed citations
17.
Carey, Thomas E., Jean B. deKernion, Robert Dreicer, et al.. (2005). Bridging the gap: Health disparity research initiatives through the department of defense (DOD) congressionally directed medical research programs (CDMRP) prostate cancer research program (PCRP). Cancer Research. 65. 599–599. 4 indexed citations
18.
Strother, John M., Tomasz M. Beer, & Robert Dreicer. (2005). Novel cytotoxic and biological agents for prostate cancer: Where will the money be in 2005?. European Journal of Cancer. 41(6). 954–964. 11 indexed citations
19.
Clark, Peter E., et al.. (2001). Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer. Urology. 57(2). 281–285. 89 indexed citations
20.
Dreicer, Robert. (1997). Metastatic prostate cancer: assessment of response to systemic therapy.. PubMed. 15(1). 28–32. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by William Kevin Kelly Breakdown of academic impact, for papers by Shahneen Sandhu Breakdown of academic impact, for papers by Glenn Liu Breakdown of academic impact, for papers by David Olmos Breakdown of academic impact, for papers by Amita Patnaik Breakdown of academic impact, for papers by Sara M. Tolaney Breakdown of academic impact, for papers by Anthony M. Joshua Breakdown of academic impact, for papers by Ian E. Krop Breakdown of academic impact, for papers by Ronit Simantov Breakdown of academic impact, for papers by A Płużańska
Rankless by CCL
2026